ID   SK-MEL-44
AC   CVCL_6040
SY   SK-Mel 44; BT-Mel
DR   Cosmic; 721827
DR   Wikidata; Q54954185
RX   DOI=10.1007/978-1-4615-7228-2_39;
RX   PubMed=2983346;
RX   PubMed=6933476;
RX   PubMed=22970293;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   48Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 21-03-23; Version: 13
//
RX   DOI=10.1007/978-1-4615-7228-2_39;
RA   Houghton A.N., Oettgen H.F., Old L.J.;
RT   "Malignant melanoma. Current status of the search for melanoma-specific
RT   antigens.";
RL   (In book chapter) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston; USA (1981).
//
RX   PubMed=2983346; DOI=10.1073/pnas.82.5.1470; PMCID=PMC397284;
RA   Dracopoli N.C., Houghton A.N., Old L.J.;
RT   "Loss of polymorphic restriction fragments in malignant melanoma:
RT   implications for tumor heterogeneity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985).
//
RX   PubMed=6933476; DOI=10.1073/pnas.77.7.4260; PMCID=PMC349812;
RA   Houghton A.N., Taormina M.C., Ikeda H., Watanabe T., Oettgen H.F.,
RA   Old L.J.;
RT   "Serological survey of normal humans for natural antibody to cell
RT   surface antigens of melanoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980).
//
RX   PubMed=22970293; DOI=10.1371/journal.pone.0044707; PMCID=PMC3435279;
RA   Zhao R.Y., Mifsud N.A., Xiao K., Chan K.-F., Oveissi S., Jackson H.M.,
RA   Dimopoulos N., Guillaume P., Knights A.J., Lowen T., Robson N.C.,
RA   Russell S.E., Scotet E., Davis I.D., Maraskovsky E., Cebon J.S.,
RA   Luescher I.F., Chen W.-S.;
RT   "A novel HLA-B18 restricted CD8+ T cell epitope is efficiently
RT   cross-presented by dendritic cells from soluble tumor antigen.";
RL   PLoS ONE 7:e44707.1-e44707.12(2012).
//